Pertuzumab, primer inhibidor de la dimerización HER

Florencia Perazzo

doi:10.56969/oc.v18i1.118

Autores/as

Florencia Perazzo Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno (CEMIC)

DOI:

https://doi.org/10.56969/oc.v18i1.118

Palabras clave:

pertuzumab, HER2, inhibidor de la dimerización, dimerization inhibitor

Resumen

Entre un 15 y un 20% de pacientes con cáncer de mama presentan amplificación o sobreexpresión de HER2, lo que le confiere un comportamiento más agresivo. Pese a que el advenimiento del trastuzumab, primer agente dirigido contra HER2, mejoró significativamente el pronóstico de este grupo de pacientes, el 50% de ellas aún progresa dentro del año de tratamiento. Pertuzumab, el primer inhibidor de la dimerización de HER2, muestra un mecanismo de acción complementario a trastuzumab, logrando mejores resultados clínicos en pacientes tratadas con ambos agentes anti-HER2 y quimioterapia. El presente trabajo repasa las propiedades de pertuzumab y su desarrollo clínico.

Citas

JemalA,BrayF,CenterMM,etal.GlobalCancerStatistics. CA Cancer J Clin 2011; 61: 69-90. DOI: https://doi.org/10.3322/caac.20107

Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, Mc-Guire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82. DOI: https://doi.org/10.1126/science.3798106

Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer administered as first-line treatment: the M77001 Study Group. J Clin Oncol 2005; 23: 4265-74. DOI: https://doi.org/10.1200/JCO.2005.04.173

Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92. DOI: https://doi.org/10.1056/NEJM200103153441101

Valero V, Forbes J, Pegram MD, et al. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene- amplified metastatic breast cancer (BCIRG 007 Study): two highly active therapeutic regimens. J Clin Oncol 2011; 29: 149-56. DOI: https://doi.org/10.1200/JCO.2010.28.6450

Nahta R, Esteva FJ. HER-2-targeted therapy: lessons learned and future directions. Clin Cancer Res 2003; 9: 5078-84.

Rosen LS, Ashurst HL, Chap L. Targeting signal transduction pathways in metastatic breast cancer: a comprehensive review. Oncologist 2010; 15: 216–35. DOI: https://doi.org/10.1634/theoncologist.2009-0145

Arpino G, Gutierrez C, Weiss H, et al. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with malignant HER-targeted therapy. J Natl Cancer Inst 2007; 99: 694-705. DOI: https://doi.org/10.1093/jnci/djk151

Jones KL, Buzdar AU. Evolving novel anti-HER2 strategies. Lancet Oncol 2009; 10: 1179-87. DOI: https://doi.org/10.1016/S1470-2045(09)70315-8

Koutras AK, Fountzilas G, Kalogeras KT, Starakis I, Iconomou G, Kalofonos HP. The upgraded role of HER3 and HER4 receptors in breast cancer. Crit Rev Oncol Hematol 2010; 74: 73-8. DOI: https://doi.org/10.1016/j.critrevonc.2009.04.011

Sliwkowski MX. Ready to partner. Nat Struct Biol 2003; 10: 158-9. DOI: https://doi.org/10.1038/nsb0303-158

Hicks DG, Kulcarni S. HER2 positive breast cancer: review of biologic relevance and optimal use of diagnostic tools. Am J Clinical Pathol 2008; 129: 263-73. DOI: https://doi.org/10.1309/99AE032R9FM8WND1

Ng CM, Lum BL, Gimenez V, et al. Rationale for fixed dosing of Pertuzumab in cancer patients based on population pharmacokinetic analysis. Pharm Res 2006; 23: 1275-83. DOI: https://doi.org/10.1007/s11095-006-0205-x

Mariani G, Strober W. Inmunoglobulin metabolism In: Fc Receptors and the action of antibodies. H. Metzger (ed). American Society of Microbiology: Washington DC, 1990, p 94-177.

Henderson LA, Baynes KW, Thorpe SR. Identification of sites of IgG catabolism in the rat. Arch Biochem Biophys 1982; 215: 1-11. DOI: https://doi.org/10.1016/0003-9861(82)90272-7

Scheuer W, Fries T, Burtscher H, Bossenmaier B, et al. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2 positive human xenograft tumor models. Cancer Res 2009; 69: 9330-6. DOI: https://doi.org/10.1158/0008-5472.CAN-08-4597

Attard G, Kitzen J, Blagden SP, et al. A phase Ib study of pertuzumab, a recombinant humanized antibody to HER2 and docetaxel in patients with advanced solid tumours. Br J Cancer 2007; 97: 1338-43. DOI: https://doi.org/10.1038/sj.bjc.6604043

Albanelli J, Montagut C, Jones ET, et al. A phase I study of safety and pharmacokinetics of the combination of pertuzumab (rhuMab 2C4) and capecitabina in patients with advanced solid tumors. Clin Cancer Res 2008; 14: 276-31. DOI: https://doi.org/10.1158/1078-0432.CCR-07-1980

Lu D, Burris HA, Wang B, et al. Drug interaction potential of trastuzumab emtansine (TDM1) combined with pertuzumab in patients with HER2 positive metastatic breast cancer. Curr Drug Metab 2012; 13: 911-22. DOI: https://doi.org/10.2174/138920012802138688

Baselga J, Cortes J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366: 109-19. DOI: https://doi.org/10.1056/NEJMoa1113216

Cortes J, Fumoleau P, Bianchi GV, et al. Pertuzumab monotherapy after trastuzumab- based treatment and subsequent reintroduction of trastuzumab activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012; 30: 1594-600. DOI: https://doi.org/10.1200/JCO.2011.37.4207

Baselga J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progress during prior trastuzumab therapy. J Clin Oncol 2010; 287: 1138-44. DOI: https://doi.org/10.1200/JCO.2009.24.2024

Gianni L, Pienkowsky L, Im YH, et al. Efficacy and safety of neadyuvant pertuzumab and trastuzumab in women con locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomized multicenter, open label, phase II trial. Lancet Oncol 2012; 13: 25-32. DOI: https://doi.org/10.1016/S1470-2045(11)70336-9

Schneeweiss A, Chia S, Hickish T, et al. Neoadjuvant pertuzumab and trastuzumab concurrent or sequential with an anthracycline-containing or concurrent with an anthracycline-free standard regimen: a randomized phase II study (TRYPHAENA). Cancer Res 2011; 71: S5-6. DOI: https://doi.org/10.1158/0008-5472.SABCS11-S5-6

Muñoz-Mateu M, Urruticoechea A, Separovic R, et al. Trastuzumab plus capecitabine with or without pertu- zumab in patients with HER2-positive MBC whose disease has progressed during or Following trastuzumab - based therapy for first-line metastatic disease: a multicenter, randomized, two-arm, phase II study (PHEREXA). J Clin Oncol 2011; 29 (suppl: abstr TPS118). DOI: https://doi.org/10.1200/jco.2011.29.15_suppl.tps118

Ellis PA, Barrios CH, Im Y, Patre M, Branle F, Perez EA. MARIANNE: a phase III, randomized study of trastuzumab-DM1 (T-DM1) with or without pertuzumab (P) compared with trastuzumab (H) plus taxane for first-line treatment of HER2-positive, progressive, or recurrent locally advanced or metastatic breast cancer (MBC). J Clin Oncol 2011; (29 suppl: abstr TPS102). DOI: https://doi.org/10.1200/jco.2011.29.15_suppl.tps102

Perez EA, Lopez-Vega JM, Mastro LD, et al. A combination of pertuzumab, trastuzumab, and vinorelbine for first-line treatment of patients with HER2- positive metastatic breast cancer: An open-label, two-cohort, phase II study (VELVET). 2012 ASCO Annual Meeting. J Clin Oncol 30, 2012 (suppl; abstr TPS653). DOI: https://doi.org/10.1200/jco.2012.30.15_suppl.tps653

Rimawi MF, Poole CJ, Ferrero JM, et al. Pertuzumab in combination with trastuzumab plus an aromatase inhibitor in patients with hormone receptor positive, HER2-positive metastatic breast cancer: A randomized phase II study (PERTAIN). 2012 ASCO Annual Meeting. J Clin Oncol 2012; 30 (suppl; abstrTPS654). DOI: https://doi.org/10.1200/jco.2012.30.15_suppl.tps654

A study of pertuzumab in combination with herceptin (trastuzumab) and a taxane in first-line treatment in patients with HER2-positive advanced breast cancer (PERUSE). Clinical Trials. gov identifier: NCT01572038. En: www.clinicaltrials.gov; consultado el 18/6/2012.